Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Research Article

A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease

Firbank M.J.a,b · Harrison R.M.b · O’Brien J.T.a

Author affiliations

aInstitute for Ageing and Health, and bRegional Medical Physics Department, Newcastle General Hospital, Newcastle upon Tyne, UK

Related Articles for ""

Dement Geriatr Cogn Disord 2002;14:64–76

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Published online: July 22, 2002
Issue release date: July 2002

Number of Print Pages: 13
Number of Figures: 5
Number of Tables: 4

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM

Abstract

We reviewed the literature of proton magnetic resonance spectroscopy (MRS) in dementia and Parkinson’s disease (PD) and quantitatively compared the reported values of the markers N-acetyl aspartate (NAA), choline, and myo-Inositol between control and disease groups. We analysed a total of 27 reports in dementia. Combining the quantitative data from these showed a relative decrease of 15% in NAA level in the temporal lobe tissue in patients with Alzheimer’s disease (AD) compared with controls. The rest of the brain showed a seemingly uniform 10% decrease in NAA levels in AD compared with controls. myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline. We found 15 reports of MRS in PD, which show a small decrease (5%) in the NAA level in the lentiform nucleus compared with controls. In progressive supranuclear palsy (PSP), there is a greater decrease in NAA levels in the frontal region and the lentiform nucleus. This may aid in the diagnosis of PSP. Further research is needed to determine spectroscopic changes in other dementias, to monitor how markers change with disease progression and to establish clinical utility.

© 2002 S. Karger AG, Basel


References

  1. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R: In vivo magnetic resonance spectroscopy of human brain: The biophysical basis of dementia. Biophys Chem 1997;68:161–172.
    External Resources
  2. Doraiswamy PM, Chen JG, Charles HC: Brain magnetic resonace spectroscopy – role in assessing outcomes in Alzheimer’s disease. CNS Drugs 2000;14:457–472.
  3. Hsu Y-Y, Du A-T, Schuff N, Weiner MW: Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. J Geriatr Psychiatry Neurol 2001;14:145–166.
    External Resources
  4. Valenzuela MJ, Sachdev P: Magnetic resonance spectroscopy in AD. Neurology 2001;56:592–598.
  5. Moffett JR, Namboodiri MAA, Cangro CB, Neale JH: Immunohistochemical localization of N-acetyl aspartate in rat brain. Neuroreport 1991;2:131–134.
  6. Simmons ML, Frondoza CG, Coyle JT: Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37–45.
  7. de Stefano NM, Matthews PM, Arnold DL: Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721–727.
  8. Kario K, Matsuo T, Hoshide S, Umeda Y, Shimada K: Effect of thrombin inhibition in vascular dementia and silent slice cerebrovascular disease. An MR spectroscopy study. Stroke 1999;30:1033–1037.
  9. Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue EW, Steinbrich W: Serial proton MR spectroscopy of contrast enhancing multiple sclerosis plaques: Absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000;21:1220–1227.
    External Resources
  10. Demougeot C, Garnier P, Mossiat C, Bertrand N, Giroud M, Beley A, Marie C: N-acetyl aspartate, a marker of both cellular dysfunction and neuronal loss: Its relevance to studies of acute brain injury. J Neurochem 2001;77:408–415.
    External Resources
  11. Sager TN, Topp S, Torup L, Hanson LG, Egestad B, Moller A: Evaluation of CA1 damage using single-voxel 1H-MRS and unbiased stereology: Can non-invasive measures of N-acetyl-aspartate following global ischemia be used as a reliable measure of neuronal damage? Brain Res 2001;892:166–175.
    External Resources
  12. Bates TE, Strangward M, Keelan J, Davey GP, Munro PMG, Clark JB: Inhibition of N-acetyl aspartate production: Implications for 1H-MRS studies in vivo. Neuroreport 1996;7:1397–1400.
  13. Bhakoo KK, Pearce D: In vitro expression of N-acetyl aspartate by oligodendrocytes: Implication for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000;74:254–262.
  14. Bitsch A, Bruhn H, Vougiokas V, Stringaris A, Lassman H, Frahm J, Bruck W: Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20:1619–1627.
  15. Chen JG, Charles HC, Barboriak DP, Doraiswamy PM: Magnetic resonance spectroscopy in Alzheimer’s disease: Focus on N-acetyl aspartate. Acta Neurol Scand 2000;176:20–26.
    External Resources
  16. Brand A, Richter-Landsberg C, Leibfritz D: Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289–298.
  17. Kinoshita Y, Yokata A: Abolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 1997;10:2–12.
  18. Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, Frahm J: Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr Neurol 1999;23:22–31.
  19. Frey R, Metzler D, Fischer P, Heiden A, Scharfetter J, Moser E, Kasper S: Myo-Inositol in depressive and healthy subjects determined by frontal 1H magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res 1998;32:411–420.
  20. Strange K: Regulation of solute and water balance and cell volume in the central nervous system. J Am Soc Nephrol 1992;3:12–27.
  21. Lien YH, Shapiro JI, Chan L: Effects of hypernatremia on organic brain osmoles. J Clin Invest 1990;85:1427–1435.
    External Resources
  22. Videen JS, Michaelis T, Pinto P, Ross BD: Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. J Clin Invest 1995;95:788–793.
  23. Geissler A, Frund R, Kohler S, Eichhorn HM, Kramer BK, Feuerbach S: Cerebral metabolite patterns in dialysis patients: Evaluation with 1H-MR spectroscopy. Radiology 1995;194:693–697.
  24. Michaelis T, Videen JS, Linsey MS, Ross BD: Dialysis and transplantation affect cerebral abnormalities of end-stage renal disease. J Magn Reson Imaging 1996;6:341–347.
  25. Kreis R, Ross BD: Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: Detection with proton MR spectroscopy. Radiology 1992;184:123–130.
  26. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D, McBride D, Jenden DJ: In vivo 1H-MRS choline: Correlation with in vitro chemistry/histology. Life Sci 1996;58:1929–1935.
    External Resources
  27. Burtscher IM, Holtas S: Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 2001;13:560–567.
  28. Urenjak J, Williams SR, Gadian DG, Noble M: Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981–989.
  29. Bothwell JH, Rae C, Dixon RM, Styles P, Bhakoo KK: Hypo-osmotic swelling-activated release of organic osmolytes in brain slices: Implications for brain oedema in vivo. J Neurochem 2001;77:1632–1640.
    External Resources
  30. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO: In vivo spectroscopic quantification of the N-acetyl moiety, creatine and choline from large volumes of brain gray and white matter: Effects of normal aging. Magn Reson Med 1999;41:276–284.
  31. Saunders DE, Howe FA, van den Boogaart A, Griffiths JR, Brown MM: Aging of the adult human brain: In vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J Magn Reson Imaging 1999;9:711–716.
  32. Leary SM, Brex PA, MacManus DG, Parker GJM, Barker GJ, Miller DH, Thompson AJ: A 1H magnetic resonance spectroscopy study of aging in parietal white matter: Implications for trials in multiple sclerosis. Magn Reson Imaging 2000;18:455–459.
  33. Ide M, Naruse S, Furuya S: 1H-MRSI of Alzheimer’s disease (in Japanese). Nippon Rinsho 1997;55:1768–1773.
  34. Salvan A-M, Ceccaldi M, Confort-Gouny S, Milandre C, Cozzone PJ, Vion-Dury J: Correlation between cognitive status and cerebral inositol in Alzheimer-type dementia. J Neurol 1998;245:686–688.
  35. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO: In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry 1999;56:185–192.
  36. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A: Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer’s disease. Lancet 2000;355:1696–1697.
  37. Lucetti C, del Dotto P, Gambaccini G, Bernardini S, Bianchi MC, Tosetti M, Bonuccelli U: Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients. Neurol Sci 2001;22:69–70.
    External Resources
  38. Shetty HU, Huang W: Measurement of myo-Inositol in biological systems by mass spectrometric and in vivo 1H magnetic resonance spectroscopic techniques. Curr Org Chem 2000;4:1–17.
  39. Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB: Brain metabolite concentration and dementia severity in Alzheimer’s disease: A 1H-MRS study. Neurology 2001;57:626–632.
    External Resources
  40. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD: Alzheimer disease: Depiction of increased cerebral myo-Inositol with proton MR spectroscopy. Radiology 1993;187:433–437.
  41. Moats RA, Ernst T, Shonk TK, Ross BD: Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110–115.
  42. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD: Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology 1995;195:65–72.
  43. Tedeschi G, Bertolino A, Lundbom N, Bonavita S, Patronas NJ, Duyn JH, Verhagen Metman L, Chase TN, di Chiro G: Cortical and subcortical chemical pathology in Alzheimer’s disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 1996;47:696–704.
  44. Longo R, Giorgini A, Magnaldi S, Pascazio L, Ricci C: Alzheimer’s disease histologically proven studied by MRI and MRS: Two cases. Magn Reson Imaging 1993;11:1209–1215.
  45. Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D, Fein G, Weiner MW: Alzheimer disease: Quantitative 1H-MR spectroscopic imaging of frontoparietal brain. Radiology 1998;207:91–102.
  46. Parnetti L, Lowenthal DT, Presciutti O, Pelliccioli G, Palumbo R, Gobbi G, Chiarini P, Palumbo B, Tarducci R, Senin U: 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer’s disease. J Am Geriatr Soc 1996;44:133–136.
  47. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, Gobbi G, Pelliccioli GP, Senin U: Proton magnetic resonance spectroscopy can differentiate Alzheimer’s disease from normal aging. Mech Ageing Dev 1997;97:9–14.
  48. Frederick BD, Satlin A, Yurgelun-Todd DA, Renshaw PF: In vivo proton magnetic resonance spectroscopy of Alzheimer’s disease in the parietal and temporal lobes. Biol Psychiatry 1997;42:147–150.
  49. Capizzano AA, Schuff N, Amend DL, Tanabe JL, Norman D, Maudsley AA, Jagust W, Chui HC, Fein G, Segal MR, Weiner MW: Subcortical ischemic vascular dementia: Assessment with quantitative MR imaging and 1H-MR spectroscopy. AJNR Am J Neuroradiol 2000;21:621–630.
  50. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R, Heun R, Schild HH: Proton MR spectroscopy detects a relative decrease of N-acetyl aspartate in the medial temporal lobe of patients with AD. Neurology 2000;55:684–688.
  51. Kantarci K, Jack CR, Xu YC, Campeau NG, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokomen E, Tangalos EG, Petersen RC: Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: A 1H-MRS study. Neurology 2000;55:210–217.
  52. Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT: MRI volumetric study of dementia with Lewy bodies: A comparison with AD and vascular dementia. Neurology 2000;54:1304–1309.
  53. Chan D, Fox NC, Scahill RI, Crum WR, Whitwell JL, Leschziner G, Rosser AM, Stevens JM, Cipolotti L, Rossor MN, et al: Patterns of temporal lobe atrophy in semantic dementia and Alzheimer’s disease. Ann Neurol 2001;49:433–442.
  54. Rose SE, de Zubicaray GI, Wang D, Galloway G, Chalk JB, Eagle SC, Semple J, Doddrell DM: A 1H MRS study of probable Alzheimer’s disease and normal aging: Implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 1999;17:291–299.
  55. Cohen BM, Renshaw PF, Stoll AL, Wurman RJ, Yurgelun-Todd DA, Babb SM: Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. JAMA 1995;274:902–907.
  56. Dechent P, Pouwels PJW, Frahm J: Neither short-term nor long-term administration of oral choline alters metabolite concentrations in human brain. Biol Psychiatry 1999;46:406–411.
  57. Satlin A, Bodick N, Offen WW, Renshaw PF: Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer’s disease: Changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry 1997;154:1459–1461.
  58. Huang W, Alexander GE, Daly EM, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB: High brain myo-Inositol levels in the predementia phase of Alzheimer’s disease in adults with Down’s syndrome: A 1H-MRS study. Am J Psychiatry 1999;156:1879–1886.
  59. Ernst T, Chang L, Melchor R, Mehringer CM: Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe 1H-MR spectroscopy. Radiology 1997;203:829–836.
  60. Christiansen P, Schlosser A, Henriksen O: Reduced N-acetyl aspartate content in the frontal part of the brain in patients with probable Alzheimer’s disease. Magn Reson Imaging 1995;13:457–462.
  61. Mackay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW: Regional grey and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996;53:167–174.
  62. Lazeyras F, Charles HC, Tupler LA, Erickson R, Boyko OB, Krishnan KRR: Metabolic brain mapping in Alzheimer’s disease using proton magnetic resonance spectroscopy. Psychiatry Res 1998;82:95–106.
  63. Stoppe G, Bruhn H, Pouwels PJW, Hanicke W, Frahm J: Alzheimer disease: Absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. Alzheimer Dis Assoc Disord 2000;14:112–119.
  64. Doraiswamy PM, Charles HC, Krishnan KRR: Prediction of cognitive decline in early Alzheimer’s disease. Lancet 1998;352:1678.
  65. Doraiswamy PM, Barboriak D, Krishnan KRR, Chen JG, Smith J, Charles HC: Brain 1H-MR spectroscopy in subjects at risk for Alzheimer’s disease. Neurobiol Aging 2001;22:338–339.
  66. Davie CA, Pirtosek Z, Barker GJ, Kingsley DPE, Miller PH, Lees AJ: Magnetic resonance spectroscopic study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry 1996;58:688–691.
  67. Federico F, Simone IL, Lucivero V, de Mari M, Giannini P, Iliceto G, Mezzapesa DM, Lamberti P: Proton magnetic resonance spectroscopy in Parkinson’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997;62:239–242.
  68. Federico F, Simone IL, Lucivero V, Iliceto G, De Mari M, Giannini P, Mezzapesa DM, Tarantino A, Lamberti P: Proton magnetic resonance spectroscopy in Parkinson’s disease and atypical parkinsonian disorders. Mov Disord 1997;12:903–909.
  69. Federico F, Simone UK, Lucivero V, Mezzapesa DM, de Mari M, Lamberti P, Petruzzellis M, Ferrari E: Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes. Ital J Neurol Sci 1999;20:223–229.
  70. Taylor-Robinson SD, Turjanski N, Bhattacharya S, Seery JP, Sargentoni J, Brooks DJ, Bryant DJ, Cox IJ: A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson’s disease. Metab Brain Dis 1999;14:45–55.
  71. Abe K, Terakawa H, Takanashi M, Watanabe Y, Tanaka H, Fujita N, Hirabuki N, Yanagihara T: Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res Bull 2000;52:589–595.
    External Resources
  72. Ellis CM, Lemmens G, Williams SCR, Simmons A, Dawson J, Leigh PN, Ray Chadhuri K: Changes in putamen N-acetyl aspartate and choline rations in untreated and levodopa-treated Parkinson’s disease: A proton magnetic resonance spectroscopy study. Neurology 1997;49:438–444.
  73. Tedeschi G, Litvan I, Bonavita S, Bertolino A, Lundbom N, Hallet M: Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson’s disease and corticobasal degeneration. Brain 1997;120:1541–1552.
    External Resources
  74. Choe B-Y, Park J-W, Lee K-S, Son B-C, Kim M-C, Kim B-S, Suh T-S, Lee H-K, Shinn K-S: Neuronal laterality in Parkinson’s disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol 1998;33:450–455.
  75. Hu MTM, Taylor-Robinson SD, Ray Chaudhuri K, Bell JD, Morris RG, Clough C, Brooks DJ, Turjanski N: Evidence for cortical dysfunction in clinically non-demented patients with Parkinson’s disease: A proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 1999;67:20–26.
  76. Holshouser BA, Komu M, Moller HE, Zijlmans J, Kolem H, Hinshaw DB, Sonninen P, Vermathen P, Heerschap A, Masur H, Rinne UK, de Koster A, Tosk JM: Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson’s disease: A multicenter pilot study. Magn Reson Med 1995;33:589–584.
  77. Cruz CJ, Aminoff MJ, Meyerhoff DJ, Graham SH, Weiner MW: Proton MR spectroscopic imaging of the striatum in Parkinson’s disease. Magn Reson Imaging 1997;15:619–624.
  78. Bowen BC, Block RE, Sanchez-Ramos J, Pattany PM, Lampman DA, Murdoch JB, Quencer RM: Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol 1995;16:61–68.
    External Resources
  79. Hoang TQ, Bluml S, Dubowitz DJ, Mats R, Kopyov O, Jacques D, Ross BD: Quantitative proton-decoupled 31P-MRS and 1H-MRS in the evaluation of Huntington’s and Parkinson’s diseases. Neurology 1998;50:1033–1040.
  80. Clarke CE, Lowry M: Basal ganglia metabolite concentrations in idiopathic Parkinson’s disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 2000;7:661–665.
  81. Zijlmans JCM, de Koster A, van ‘t Hof MA, Thijssen HOM, Horstink MWIM, Heerschap A: Proton magnetic resonance spectroscopy in suspected vascular ischemic Parkinsonism. Acta Neurol Scand 1994;90:405–411.
  82. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW: Changes of hippocampal N-acetyl aspartate and volume in Alzheimer’s disease. Neurology 1997;49:1513–1521.
  83. Davie CA, Wenning GK, Barker GJ, Tofts PS, Kendall BE, Quinn N, McDonald WI, Marsden CD, Miller DH: Differentiation of multiple system atrophy from idiopathic Parkinson’s disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204–210.
  84. Keevil SF, Barbiroli B, Brooks JCW, Cady EB, Canese R, Carlier P, Collins DJ, Gilligan P, Gobbi G, Hennig J, Kugel H, Leach MO, Metzler D, Mlynarik V, Moser E, Newbold MC, Payne GS, Ring P, Roberts JN, Rowland IJ, Thiel T, Tkac I, Topp S, Wittsack HJ, Wylezinska M, Zaniol P, Henriksen O, Podo F: Absolute metabolite quantification by in vivo NMR spectroscopy. 2. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging 1998;16:1093–1106.
  85. Kreis R, Ernst T, Ross BD: Absolute quantification of water and metabolites in the human brain. 2. Metabolite concentrations. J Magn Reson B 1993;102:9–19.
    External Resources
  86. Mierisova S, Ala-Korpela M: MR spectroscopy quantitation: A review of frequency domain methods. NMR Biomed 2001;14:247–259.
  87. Vanhamme L, Sundin T, van Hecke P, van Huffel S: MR spectroscopy quantitation: A review of time-domain methods. NMR Biomed 2001;14:233–246.
  88. von Block W, Traber F, Kuhl CK, Fric M, Keller E, Lamerichs R, Rink H, Moller HJ: 1H-MR spectroscopic imaging in patients with Alzheimer’s disease (in German). Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 1995;163:230–237.
    External Resources
  89. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli G, Piccirilli M, Gobbi G, Senin U, Mecocci P: 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001;12:2315–2317.
  90. Heun R, Schlegel S, Graf-Morgenstern M, Tintera J, Gawehn J, Stoeter P: Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Int J Geriatr Psych 1997;12:349–358.
  91. Meyerhoff DJ, MacKay S, Constans JM, Norman D, van Dyke C, Fein G, Weiner MW: Axonal injury and membrane alterations in Alzheimer’s disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol 1994;36:40–47.
  92. Shiino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J: Proton magnetic resonance spectroscopy with dementia. Surg Neurol 1993;39:143–147.
  93. Brooks WM, Wesley MH, Kodituwakku PW, Garry PJ, Rosenberg GA: 1H-MRS differentiates white matter hyperintensities in subcortical arteriosclerotic encephalopathy from those in normal elderly. Stroke 1997;28:1940–1943.
  94. Constans JM, Meyerhoff DJ, Gerson J, MacKay S, Norman D, Fein G, Weiner MW: 1H-MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia. Radiology 1995;19:517–523.
  95. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA: Proton magnetic resonance spectroscopy of vascular and Alzheimer type dementia. Arch Neurol 1996;53:678–680.
  96. Rai GS, McConnell JR, Waldman A, Grant D, Chaudry M: Brain proton spectroscopy in dementia: An aid to clinical diagnosis. Lancet 1999;353:1063.
  97. Clarke CE, Lowry M, Horsman A: Unchanged basal ganglia N-acetyl aspartate and glutamate in idiopathic Parkinson’s disease measured by proton magnetic resonance spectroscopy. Mov Disord 1997;12:297–301.

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Published online: July 22, 2002
Issue release date: July 2002

Number of Print Pages: 13
Number of Figures: 5
Number of Tables: 4

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: https://www.karger.com/DEM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.